Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Rett syndrome

Economic impact of diagnostic testing

6 evidence topics · 6 sources

US laboratory list prices: pediatric hospital molecular diagnostics laboratory, 2026
TestCPT code2026 priceCPT code, known familial variant2026 price, known familial variant
MECP2 sequencing“81302”“$685”“81303”“$225”
MECP2 deletion/duplication“81304”“$300”“81303”“$300”
US laboratory list prices: MECP2 Sanger sequencing at a genetics center
Canadian testing costs, turnaround, and out-of-pocket costs: trofinetide reimbursement review

“The total cost of MECP2 testing is approximately $1,307.45 per sample, which includes:” (opens the source at this quote in a new tab)

“$1,172.42 for Sanger sequencing and MLPA (i.e., $586.21 for each test processed in Alberta)” (opens the source at this quote in a new tab)

“The anticipated cost of ordering an MECP2 sequence and CNV detection test using NGS is US$990;” (opens the source at this quote in a new tab)

“according to a molecular testing inventory scan, the turnaround time in Alberta varies from 1 week to 2 weeks for urgent testing and from 6 weeks to 8 weeks for routine testing with both Sanger sequencing and MLPA.” (opens the source at this quote in a new tab)

“From the targeted jurisdictional survey, British Columbia indicated that in cases of MECP2 testing not approved for provincial reimbursement, out-of-pocket costs may be incurred by patients and their families.” (opens the source at this quote in a new tab)

“Repeat testing is not required once the MECP2 mutation status is confirmed.” (opens the source at this quote in a new tab)

“Based on the relatively low number of individuals estimated to be diagnosed with Rett syndrome each year, and because testing may already be routinely conducted in Canada to confirm the diagnosis of Rett syndrome, if trofinetide becomes funded, the provision of MECP2 testing is not anticipated to have a substantial impact on human or other health care resources.” (opens the source at this quote in a new tab)